Physician profile
Suzanne Daly
NPI 1780770446
$770.32
in general payments reported to CMS, 2019-2025
11 companies · $412 in 2025
The $412 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $11.38 · 2021: $97.75 · 2023: $125 · 2024: $124 · 2025: $412.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $639 · Education: $22.16.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $639.03 |
| Education | $22.16 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $183.41 | 2021-2025 | Skyrizi, Rinvoq |
| Madrigal Pharmaceuticals | $180.89 | 2025 | Rezdiffra |
| Aimmune Therapeutics, INC. | $147.31 | 2025 | Zenpep |
| Janssen Biotech, INC. | $66.21 | 2024-2025 | Tremfya, Stelara |
| Nestle Healthcare Nutrition INC. | $54.15 | 2020-2023 | |
| Regeneron Healthcare Solutions, INC. | $43.65 | 2023-2025 | Dupixent |
| Phathom Pharmaceuticals, INC. | $28.89 | 2024 | Voquezna |
| Echosens North America, INC. | $19.54 | 2023 | Fibroscan |
| Eisai INC. | $18.40 | 2024 | |
| Boston Scientific Corporation | $14.33 | 2021 | |
| Intercept Pharmaceuticals, INC. | $13.54 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Suzanne Daly listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.